Stephen Liu, MD, on the Impact the IMpower010 Trial at ASCO 2021

Video

At ASCO 2021, Stephen Liu, MD, discussed his excitement for results of the IMpower010 trial of atezolizumab in patients with early-stage resected non–small cell lung cancer

CancerNetwork® sat down with Stephen Liu, MD, of the Georgetown Lombardi Comprehensive Cancer Center, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about the results of the phase 3 IMpower010 trial (NCT02486718) of atezolizumab (Tecentriq) versus best supportive care for the treatment of patients with stage IB to IIIA surgically resected non–small cell lung cancer.

Transcription

I think at ASCO 2021, the one abstract we’re really waiting to see and the results that we want to pour over are the results from IMpower010. This is the adjuvant study of atezolizumab and the first study showing us a benefit with immunotherapy after surgical resection compared with placebo in a randomized trial. Looking at immunotherapy for patients with completely resected non–small cell lung cancer after chemotherapy and immunotherapy has been a transformative treatment for metastatic lung cancer. We also know that for patients with resected lung cancer, while our goal is cure, it’s not always our expectation. Lung cancer is a very difficult disease to eradicate. Implementing immunotherapy in that setting really can improve our outcomes and extend the cure to more people coupled with earlier detection and screening. I think this has a chance to make a huge impact for patients with lung cancer.

Reference

Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(suppl 15):8500. doi:10.1200/JCO.2021.39.15_suppl.8500

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content